MarketVIEW: Candida vaccines

Feb 18, 2013, 07:33 ET from Reportlinker

NEW YORK, Feb. 18, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

MarketVIEW: Candida vaccines

http://www.reportlinker.com/p0961701/MarketVIEW-Candida-vaccines.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Candida yeasts cause Candidiasis which is a fungal infection commonly found in humans. Infections can occur in the female Genital area "vulvovaginal candidiasis" of which nearly 75% of all adult women have had one "yeast infection" in their lifetime. Some women experience recurrent episodes (RVVC) which can cause considerable inconvenience and distress. Invasive Candidiasis, is a life threatening infection which mainly affects individuals with serious underlying co-morbidities. Infections usually occur in the hospital intensive care unit (ICU) where it is the fourth most common bloodstream infection (CDC Figures). 

This MarketVIEW This MarketVIEW product is a comprehensive MS Excel-based model + summary presentation which forecasts the potential commercial value of Candida vaccines across major Western markets until 2030. The model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, pricing and penetration estimates for both Recurrent Vulvovaginal Candidiasis (RVVC) and invasive Candidiasis (in the ICU setting) indications. For RVVC indication 3 prevalence scenarios (LO/MID/HI) are included. The product also includes an up-to-date review of latest competitor activity in the field and Candida epidemiology. 

THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL

Executive SummaryRVVC TX vaccine: available market ($000s) to 2030, realistic RVVCprevalenceRVVC TX vaccine: available market ($000s) to 2030 by conservative,realistic and optimistic RVVC prevalenceRVVC TX vaccine: available market (000s doses) to 2030Candida ICU PX vaccine: available market ($000s) to 2030Candida ICU PX vaccine: available market (000s doses) to 2030The role of Candida vaccinesCandida ICU PX vaccine: target product profileRVVC TX vaccine: target product profileCandida ICU PX vaccine: model assumptionsRVVC TX vaccine: model assumptionsKey commercial model assumptionsPricingCompetitor landscape: overviewPevion (PEV7)NovaDigm Therapeutics (NDV-3)Vulvovaginal candidiasis: overviewVulvovaginal candidiasis: surveillanceVulvovaginal candidiasis: regional dataVulvovaginal candidiasis: primary care consultationsVulvovaginal candidiasis: drug utilizationVulvovaginal candidiasis: drug utilizationVulvovaginal candidiasis: population based studiesVulvovaginal candidiasis: incidence/prevalence summaryInvasive candidiasis: overviewInvasive candidiasis: national surveillance dataInvasive candidiasis: estimating ICU admissionsBibliographyDisclaimerAbout VacZine AnalyticsPAGES: 50 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents – Vaccine demand model (MS Excel-based)

Title

Scenarios

Charts value (RVVC)

Charts value (ICU)

Charts volume (RVVC and ICU)

Value summary (ICU)

Volume summary (ICU)

Value summary (RVVC)

Volume summary (RVVC)

Model inputs (RVVC)

ICU patients =>

US (ICU)

UK (ICU)

CANADA (ICU)

GERMANY (ICU)

SPAIN (ICU)

FRANCE (ICU)

ITALY (ICU)

EU other (ICU)

AUSTRALIA (ICU)

JAPAN (ICU)

RVVC patients =>

LO/BASE/HI prevalence scenarios

US (RVVC)

UK (RVVC)

CANADA (RVVC)

GERMANY (RVVC)

SPAIN (RVVC)

FRANCE (RVVC)

ITALY (RVVC)

EU other (RVVC)

AUSTRALIA (RVVC)

JAPAN (RVVC)

Source material ?

ICU database

RVVC database

UK RVVC epi

US ICU epi

Back page

Worksheets = >60 interconnected

To order this report:: MarketVIEW: Candida vaccines

Nicolas Bombourg
Reportlinker
Email: nicolasbombourg@reportlinker.com
US: (805)652-2626
Intl: +1 805-652-2626

 

SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com